FDA Approves Orca Bio Tregzi T-Cell Therapy to Cut GVHD Risk in Stem Cell Transplants

The approval rests on a registrational trial that randomized patients to Tregzi or standard calcineurin-inhibitor prophylaxis after myeloablative conditioning. At one year, chronic GVHD-free survival reached 66 percent with Tregzi versus 38 percent in controls, driven by a 42 percent absolute reduction in moderate-to-severe chronic GVHD; overall survival curves separated modestly but did not yet reach statistical significance. The product is manufactured from the same donor apheresis used for the stem-cell graft, requiring coordinated logistics between transplant centers and Orca’s centralized facility.

Prior approvals of post-transplant cyclophosphamide and abatacept addressed acute GVHD; Tregzi targets the chronic phase that drives long-term morbidity. This distinction matters because chronic GVHD remains the leading cause of non-relapse mortality beyond day 100. Real-world data from the CIBMTR registry show that even mild chronic GVHD doubles five-year medical costs and halves quality-adjusted life years, underscoring the economic case for Tregzi if pricing stays below $450 000 per course.

Orca’s approach differs from CAR-T constructs by preserving graft-versus-leukemia activity while selectively expanding donor regulatory T cells; this mechanistic separation may avoid the infection and secondary-malignancy signals seen with broad T-cell depletion. Payers will likely require outcomes-based contracts tied to two-year GVHD-free survival, given the absence of head-to-head data versus post-transplant cyclophosphamide platforms.

Next steps include a planned phase 3 trial in reduced-intensity regimens and a post-marketing registry to track rare infusion reactions and manufacturing failures. Reimbursement negotiations with Medicare and commercial plans begin this quarter.